Insiders · BCLI

Irit Arbel

Director at Brainstorm Cell Therapeutics Inc. (BCLI)

Irit Arbel has filed 4 insider reports with the SEC since December 2021, as director at Brainstorm Cell Therapeutics Inc. (BCLI). The latest filing, on May 29, 2026, reports grant or award at Brainstorm Cell Therapeutics Inc. (BCLI).

Filings
4
Companies
1
Bought on market
None
Sold on market
None

Companies where Irit Arbel is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Brainstorm Cell Therapeutics Inc. logo
BCLI
Brainstorm Cell Therapeutics Inc.
Director161,054May 29, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Irit Arbel with

Other insiders at the same companies

Questions about Irit Arbel

What is Irit Arbel's role at Brainstorm Cell Therapeutics Inc.?
Irit Arbel reports to the SEC as director at Brainstorm Cell Therapeutics Inc. (BCLI), according to the latest filing on May 29, 2026.
How many shares does Irit Arbel own?
After the latest filing that states it, Irit Arbel directly owned 161,054 shares of Brainstorm Cell Therapeutics Inc. (BCLI). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Irit Arbel bought or sold stock recently?
No open-market purchases or sales by Irit Arbel are on file. The filings report grant or award.
How do I get alerts when Irit Arbel files?
Follow Irit Arbel on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Irit Arbel (SEC CIK 0001245607). Totals count each trade once, skipping amendments whose original is on file, from Dec 11, 2021 on. View on SEC EDGAR